Review analyzes oxidative stress pathways and inflammaging in inflammatory bowel disease

A literature review published in Expert Review of Gastroenterology & Hepatology outlines how targeting redox homeostasis, including the Nrf2 pathway and ferroptosis suppression, could offer novel adjunctive therapies for inflammatory bowel diseases by mitigating inflammaging.

Researchers at the Medical University of Lodz published a comprehensive literature review analyzing data from February 2013 to September 2026 regarding the pathogenic role of oxidative stress in inflammatory bowel disease (IBD).

The review highlights therapeutic interventions targeting dysregulated redox homeostasis, specifically evaluating the therapeutic potential of Nrf2 signaling pathway activation and the suppression of ferroptosis.

The authors discussed the role of inflammaging and targeted dietary interventions as therapeutic levers to modulate redox status and influence chronic mucosal inflammatory pathways.

Current pharmacological interventions for IBD focus on symptom management and broad immunosuppression but are not curative, highlighting a critical clinical gap for adjunctive therapeutics targeting upstream pathogenic drivers.

By linking redox biology, mitochondrial health, cellular aging (inflammaging), and the microbiome, the review outlines a multi-layered mechanistic framework for intervention in chronic, age-associated inflammatory disorders.

The academic and preclinical emphasis on the Nrf2 pathway and ferroptosis suppression may encourage early-stage biotechs to leverage their existing anti-aging pipelines for targeted, organ-specific indications like IBD.

The highlighted utility of nanoparticle-based drug delivery systems points to a critical technological bottleneck and intellectual property focus for developers of localized gastrointestinal therapeutics.

Preclinical validation and early clinical transition of selective Nrf2 agonists and ferroptosis inhibitors formulated specifically for gastrointestinal delivery.